Articles related to Cardiology

Nearly 89% of U.S. ischemic heart disease deaths in 2023 were attributable to modifiable risk factors, according to Global Burden of Disease data. Mortality rates declined substantially since 1990, although deaths linked to elevated BMI and fasting glucose increased.

The FDA approved enlicitide (Lipfendra), the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia. Approval was based on substantial LDL-C reductions, while cardiovascular outcomes data remain pending.

Pregnancy is well tolerated for many women with congenital heart disease, but outcomes vary substantially by underlying lesion and clinical characteristics. Current guidance emphasizes multidisciplinary counseling, structured risk assessment, and individualized management before conception.

A phase 2b trial found that biweekly bofanglutide significantly reduced HbA1c levels and produced weight loss in adults with type 2 diabetes. The findings add to ongoing development of longer-interval GLP-1 therapies, though larger and longer studies remain necessary.

The reported death of Senator Lindsey Graham following a suspected aortic dissection has renewed attention on a condition that can mimic other cardiovascular emergencies. Existing guidelines emphasize surveillance, risk-factor management, and timely recognition in high-risk patients.

Objective sleep measurements from nearly 61,000 adults linked greater sleep regularity with lower all-cause, cancer, and cardiometabolic mortality risk. Sleep regularity outperformed sleep duration in mortality prediction models.